Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
The company’s PAT rose 43.7% year-on-year to Rs. 45.3 crore in Q4FY26 from Rs. 31.5 crore
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
Germany will be the first launch market
CSPC will receive an upfront payment of $100 million from AstraZeneca
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
Subscribe To Our Newsletter & Stay Updated
